VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Abbott Laboratories vs AstraZeneca PLC
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Abbott Laboratories
ABT · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Abbott Laboratories's moat claims, evidence, and risks.
View ABT analysisAstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisComparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 64 / 100 for Abbott Laboratories).
- Segment focus: Abbott Laboratories has 7 segments (26.7% in Cardiovascular & Electrophysiology Devices); AstraZeneca PLC has 6 segments (41% in Oncology).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Abbott Laboratories has 10 moat types across 3 domains; AstraZeneca PLC has 4 across 3.
Primary market context
Abbott Laboratories
Cardiovascular & Electrophysiology Devices
Cardiovascular, electrophysiology, rhythm management, structural heart and heart failure devices
Global
Hospitals, ambulatory surgery centers, cardiologists/electrophysiologists
Implantable device manufacturer
26.7%
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Side-by-side metrics
Moat coverage
Shared moat types
Abbott Laboratories strengths
AstraZeneca PLC strengths
Segment mix
Abbott Laboratories segments
Full profile >Established Pharmaceutical Products
Competitive
Diagnostic Products
Oligopoly
Pediatric Nutrition
Oligopoly
Adult Nutrition
Oligopoly
Diabetes Care (CGM & glucose monitoring)
Duopoly
Cardiovascular & Electrophysiology Devices
Oligopoly
Neuromodulation Devices
Oligopoly
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.